Zobrazuji výsledky 1 - 5 z 5 pro vyhledávání 'Leslie E. Oldfield (16797703)', doba hledání: 0,01 s. Upřesnit hledání
  1. 1
    Supplementary Table S4 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S4 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... Autor Stephanie Lheureux (16797697)

    Vydáno 2025
    Další autoři:
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Supplementary Table S5 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S5 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... Autor Stephanie Lheureux (16797697)

    Vydáno 2025
    Další autoři:
    Přidat do oblíbených
    Uloženo v:
  3. 3
    Supplementary Table S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... Autor Stephanie Lheureux (16797697)

    Vydáno 2025
    Další autoři:
    Přidat do oblíbených
    Uloženo v:
  4. 4
    Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... Autor Stephanie Lheureux (16797697)

    Vydáno 2025
    Další autoři:
    Přidat do oblíbených
    Uloženo v:
  5. 5
    Supplementary Table S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... Autor Stephanie Lheureux (16797697)

    Vydáno 2025
    Další autoři:
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: